2020-05-07T09:11:23-05:00 2019-06-30 431985162 SMITH SULLIVAN & BROWN PC 80 FLANDERS ROAD - SUITE 200 WESTBOROUGH MA 01581 990 2018-07-01 471981973 COHEN VETERANS BIOSCIENCE INC COHE 6469704325 1 BROADWAY 14TH FLOOR CAMBRIDGE MA 02142 MAGALI HAAS MD PHD CEO & PRESIDENT 6469704325 2020-05-07 1 SANDRA M BROWN CPA P01614103 5088717178 2020-05-07 71.248.188.134 2020-05-07 09:51:08 ED P 60516F29906696E45DA798F791FFF32AB745D411 69E9977AC052CEB93F1ED3E2D4B07C277CAC5DE2 2018 2020-11-19 02:30:22Z MAGALI HAAS MD PHD 1 BROADWAY 14TH FLOOR CAMBRIDGE MA 02142 21039448 0 X WWW.COHENVETERANSBIOSCIENCE.ORG X 2014 MA COHEN VETERANS BIOSCIENCE, INC. IS A NATIONAL 501(C)(3) RESEARCH BIOTECH DEDICATED TO FAST-TRACKING THE DEVELOPMENT OF DIAGNOSTIC TESTS AND PERSONALIZED THERAPEUTICS FOR THE MILLIONS OF VETERANS AND CIVILIANS WHO SUFFER THE DEVASTATING EFFECTS OF TRAUMA-RELATED AND OTHER BRAIN DISORDERS. 4 2 25 0 0 0 16828176 20795052 0 0 17365 98872 0 145524 16845541 21039448 5034699 2786841 0 0 2674809 4994068 0 0 53373 7087152 12390028 14796660 20170937 2048881 868511 16353364 24190269 6020527 12988921 10332837 11201348 X WCOHEN VETERANS BIOSCIENCE, INC. IS A NATIONAL 501(C)(3) RESEARCH BIOTECH DEDICATED TO FAST-TRACKING THE DEVELOPMENT OF DIAGNOSTIC TESTS AND PERSONALIZED THERAPEUTICS FOR THE MILLIONS OF VETERANS AND CIVILIANS WHO SUFFER THE DEVASTATING EFFECTS OF TRAUMA-RELATED AND OTHER BRAIN DISORDERS. 0 0 18881114 2786841 BRAIN HEALTH PLATFORMSIN ORDER TO FAST-TRACK PRECISION DIAGNOSTICS AND PERSONALIZED THERAPEUTICS AND WELLNESS APPROACHES FOR MAINTENANCE AND RESTORATION OF BRAIN HEALTH, CVB IS LEVERAGING INNOVATION AND TECHNOLOGY TO BUILD PLATFORMS THAT ENABLE DISCOVERY AND DEVELOPMENT ACROSS BRAIN DISEASES. THESE PLATFORMS ALLOW RESEARCHERS FROM ACADEMIA AND INDUSTRY TO ACCESS AND UTILIZE BEST-IN-CLASS TOOLS AND ALLOW EFFORTS TO BE SCALED WITH RIGOR AND REPRODUCIBILITY.(SEE SCHEDULE O FOR FULL DETAIL OF OUR PROGRAMS)PLATFORM EFFORTS FOCUS ON CAPACITY THAT ENABLES RELIABLE DISCOVERY OF BIOMARKERS AND BIOLOGICAL PATHWAYS THAT ARE TRANSLATIONALLY RELEVANT FOR THE DEVELOPMENT OF DIAGNOSTICS AND THERAPEUTIC TARGETS FOR DRUG AND OTHER MEDICAL INTERVENTIONS. EACH PLATFORM IS CREATING RESEARCH TOOLS (E.G. ANIMAL MODELS, DATA STANDARDS, COMPUTATIONAL MODELS, REFERENCE DATABASES, ETC.) THAT WILL ACCELERATE/FOSTER THESE DISCOVERIES. WITHIN THIS FRAMEWORK, CVB HAS ESTABLISHED BOTH INTRAMURAL (RESEARCH CONDUCTED BY, OR INCLUDING, CVB STAFF OR CONTRACTORS) AND EXTRAMURAL RESEARCH PROGRAMS (RESEARCH CONDUCTED VIA GRANTS OR IN COLLABORATION WITH EXTERNAL ACADEMIC, INDUSTRY, FOUNDATION AND GOVERNMENT PARTNERS) AND ALSO OPERATES SEVERAL PUBLIC-PRIVATE PARTNERSHIPS. THESE COOPERATIVE ALLIANCES, ORGANIZE AND FUND A NETWORK OF PARTNERS WHO EACH CONTRIBUTE COMPLEMENTARY AND SYNERGISTIC DATA, CAPABILITIES, OR EXPERTISE TO SUPPORT A COMMON ROADMAP FOR IDENTIFYING DIAGNOSTIC BIOMARKERS, BUILDING PREDICTIVE BRAIN DISEASE MODELS, DEVELOPING ROBUST STANDARDIZED TRANSLATIONAL TOOLS, AND CATALYZING PHARMACEUTICAL DRUG DEVELOPMENT. THE EMPHASIS IS ON TEAM SCIENCE WITH COHEN VETERANS BIOSCIENCE SERVING AS ITS HUB.OUR PLATFORM PROGRAMS CURRENTLY INCLUDE THE BRAIN COMMONS (CLOUD-BASED DATA SHARING), EARLYSIGNAL (WEARABLE AND HOME SENSORS FOR MONITORING HEALTH STATUS), GLOBAL PRECLINICAL DATA FORUM (DEVELOPING ROBUST, REPRODUCIBLE AND TRANSLATIONAL PRECLINICAL MODELS) AND RAPID-DX (ESTABLISHING BEST PRACTICES FOR DISCOVERY AND VALIDATION OF BIOMARKERS) AND BRAIN-NET (A CLINICAL TRIAL INFRASTRUCTURE TO EXECUTE TURN-KEY EARLY PHASE CLINICAL STUDIES).BRAIN COMMONS(TRADEMARKED):IN PARTNERSHIP WITH THE OPEN COMMONS CONSORTIUM AND UNIVERSITY OF CHICAGO, CVB HAS CREATED A CLOUD-ACCESSIBLE AND SECURE DIGITAL ECOSYSTEM TO ENABLE AND STIMULATE DATA SHARING AND ANALYSIS IN BOTH PUBLIC AND PRIVATE DOMAINS, FUELING DISCOVERY AND COLLABORATION ACROSS THE MULTIDISCIPLINARY RESEARCH COMMUNITY, AND DRIVING DIAGNOSTIC AND THERAPEUTIC INNOVATION TO REDUCE THE BURDEN OF BRAIN-BASED DISORDERS.IN 2019, WE EXPANDED ACCESS OF THE PLATFORM TO LEADING BRAIN-RELATED DISEASE FOUNDATIONS TO HOUSE THEIR OWN DATA WITHIN THE COMMONS. EARLYSIGNAL(TRADEMARKED): WEARABLE AND SENSOR TECHNOLOGIES HOLD PROMISE IN THE ASSESSMENT AND CONTINUOUS MONITORING OF PATIENTS IN ORDER TO BETTER SCREEN AND DIAGNOSE, MONITOR DISEASE PROGRESSION, AND OBSERVE INTERVENTION RESPONSE OR LACK THEREOF. DIGITAL HEALTH MONITORING ALSO ALLOWS US TO STUDY BRAIN HEALTH AND DISEASE IN UNPRECEDENTED WAYS BY TRACKING VARIABLES SUCH AS SLEEP, PHYSICAL ACTIVITY, STRESS AND COGNITION, WE MAY BE ABLE TO BETTER UNDERSTAND WHAT CHANGES OVER TIME - AND TO DEVELOP EARLIER AND PREVENTIVE DIAGNOSTICS AND TREATMENTS TO MAKE A DIFFERENCE IN PATIENTS' LIVES. MEDICAL-GRADE DATA IS NEEDED FOR FDA APPROVAL OF SUCH PLATFORMS FOR USE IN MEDICAL DECISION MAKING AND DATA INTEGRATION IS NECESSARY FOR CLINICIANS' WORKFLOW. THIS PROGRAM SUPPORTS MULTIPLE PARTNERS TO TEST AND VALIDATE WEARABLES, SENSORS, APPS AND OTHER DIGITAL HEALTH TECHNOLOGIES FOR USE IN MONITORING BRAIN HEALTH.RAPID-DIAGNOSTICS (RAPID-DX):A BIOMARKER IS A CHARACTERISTIC THAT IS OBJECTIVELY MEASURED AND EVALUATED AS AN INDICATOR OF A NORMAL OR PATHOLOGIC BIOLOGICAL PROCESS OR A RESPONSE TO A THERAPEUTIC INTERVENTION. DEVELOPING BIOMARKER-BASED DIAGNOSTICS IS ESSENTIAL TO SHIFTING DIAGNOSIS AND TREATMENT OF PSYCHIATRIC AND NEUROLOGIC CONDITIONS (SUCH AS PTSD AND TBI) FROM A SYNDROMIC OR SYMPTOM-BASED APPROACH TO A BIOLOGICAL, MECHANISTICALLY-BASED ONE THAT TARGETS THE EFFECTS OF TRAUMA AT THEIR MOLECULAR ROOTS. MANY POTENTIAL BRAIN-RELATED BIOMARKERS PUBLISHED IN THE LITERATURE HAVE NOT BEEN INDEPENDENTLY REPLICATED OR ADVANCED THROUGH A QUALIFICATION PROCESS FOR REGULATORY APPROVAL AND USE.RAPID-DX IS A PUBLIC-PRIVATE PARTNERSHIP PROGRAM INCLUDING GOVERNMENT, FOUNDATIONS, AND LEADING ACADEMIC CENTERS ESTABLISHED FOR COLLECTING DATA AND PERFORMING STUDIES NECESSARY TO DISCOVER AND REPLICATE BIOMARKERS AND QUALIFY SUCCESSFUL AND RELEVANT CANDIDATES FOR DEVELOPMENT AS CLINICAL DIAGNOSTICS.THROUGH THIS PROGRAM CVB HAS ESTABLISHED THE CVB BRAIN BIOREPOSITORY IN PARTNERSHIP WITH INDIANA UNIVERSITY. THE GOAL OF THE BIOREPOSITORY IS TO ESTABLISH A CENTRALIZED RESOURCE FOR TISSUE AND BIOSAMPLE STORAGE FOR ENABLING BIOMARKER DISCOVERY, REPLICATION, AND VALIDATION ACROSS A NUMBER OF BRAIN CONDITIONS, INCLUDING POST-TRAUMATIC STRESS DISORDER (PTSD), TRAUMATIC BRAIN INJURY (TBI), SUICIDE, DEMENTIA, MAJOR DEPRESSIVE DISORDER AND OTHER MENTAL HEALTH DISORDERS.THE CVB BRAIN BIOREPOSITORY HOUSES BLOOD AND SALIVA SAMPLES THAT WERE COLLECTED AS PART OF BIOMARKER STUDIES DIRECTLY SPONSORED BY COHEN VETERANS BIOSCIENCE OR THROUGH KEY PARTNERSHIP PROGRAMS. OUR BIOREPOSITORY BANKS A VARIETY OF BIOLOGIC SAMPLES INCLUDING, BUT NOT LIMITED TO, PLASMA, SERUM, AND SALIVA, AND WILL ENCOURAGE FUTURE COLLABORATIONS WITH RESEARCHERS FROM ACADEMIA, INDUSTRY, GOVERNMENT AND FOUNDATIONS.BRAIN-NET(TRADEMARKED):DRUG DEVELOPMENT IS COSTLY, TIME-CONSUMING, AND INEFFICIENT. MANY OPPORTUNITIES EXIST TO IMPROVE OPERATIONAL EXCELLENCE, TRIAL DESIGN, AND PATIENT RECRUITMENT. CVB IS ESTABLISHING A WELL-FUNDED, WELL-TRAINED, FAST-START, STANDING NETWORK OF BRAIN-RELATED CLINICAL TRIAL WHICH SITES WOULD PROMOTE THE DEVELOPMENT OF NEW AGENTS FOR BRAIN CONDITIONS SUCH AS PTSD, MDD, ANXIETY, CHRONIC EFFECTS OF TBI TO REDUCE TIME AND COSTS ASSOCIATED WITH DRUG DEVELOPMENT. THIS NETWORK WILL HAVE A FOCUS ON PRECISION THERAPEUTICS APPROACHES AND WILL IMPLEMENT CAPABILITIES FROM OUR OTHER PLATFORMS. BRAIN TRAUMA PROGRAMS: POST TRAUMATIC STRESS DISORDER ("PTSD") AND TRAUMATIC BRAIN INJURY ("TBI"):IN JULY 2015, THIS CVB PROGRAM WAS FOUNDED TO ESTABLISH A NATIONAL RESEARCH ROADMAP FOR PTSD, TBI AND RELATED CONDITIONS (E.G. SUICIDALITY). BRAIN TRAUMA BLUEPRINT - STATE OF THE SCIENCE SUMMITS:THE BRAIN TRAUMA BLUEPRINT IS A SERIES OF STATE OF THE SCIENCE SUMMITS("SOSS") AIMED TO BUILD CONSENSUS AROUND KNOWLEDGE GAPS AND DEVELOP STRATEGIES TO MOVE THE FIELD FORWARD FOR TRAUMA-RELATED CONDITIONS BY LEVERAGING THE COMBINED INTELLECTUAL RESOURCES OF THE FULL RESEARCH COMMUNITY.THE STATE OF THE SCIENCE SUMMITS ARE DESIGNED AS 2-DAY RETREATS FOR 100 TO 200 STAKEHOLDERS TO COME TOGETHER TO REALIZE TRUE IMPACT. THE STAKEHOLDERS WILL ENCOMPASS A BROAD SWATH OF THE COMMUNITY FROM ACADEMIC INSTITUTIONS TO GOVERNMENT AGENCIES, FOUNDATIONS SUPPORTING TRANSLATIONAL RESEARCH, AND INDUSTRY.EACH SUMMIT SERVES AS A LAUNCHPAD FOR ONGOING WORKING GROUPS TO DEVELOP EVIDENCE-BASED STRATEGIES AND RECOMMENDATIONS ON HOW TO FILL THOSE GAPS, IDENTIFY NEW GAPS AS OTHERS ARE FILLED, AND DISSEMINATE THESE FINDINGS BACK TO THE COMMUNITY AT LARGE THROUGH WHITE PAPERS AND PROCEEDINGS.THE INAUGURAL STATE OF THE SCIENCE SUMMIT, HELD IN SEPTEMBER 2018, FOCUSED ON DIAGNOSIS OF TRAUMA-RELATED BRAIN DISORDERS WITH A MAJOR FOCUS ON POST-TRAUMATIC STRESS DISORDER. THE TRAUMA-RELATED BRAIN DISORDERS RESEARCH COMMUNITY HAS IDENTIFIED A NEED TO ESTABLISH A MECHANISM-BASED TAXONOMY FOR THESE CONDITIONS TO ADVANCE BIOMARKER DISCOVERY AS WELL AS DIAGNOSIS AND THERAPEUTIC DEVELOPMENT. A SHIFT FROM A SYNDROMIC CLASSIFICATION SYSTEM TO A MECHANISTIC ONE NECESSITATES A REVIEW OF THE CURRENT SCIENTIFIC KNOWLEDGE, ADOPTION OF NEW SCIENTIFIC MODELS, AND IDENTIFICATION OF RESEARCH AND KNOWLEDGE GAPS. THE SOSS BROUGHT TOGETHER MULTIDISCIPLINARY STAKEHOLDERS WITH DEEP SCIENTIFIC AND CLINICAL EXPERTISE TO ADDRESS THIS PRESSING NEED.THE THEME OF THE SECOND STATE OF THE SCIENCE SUMMIT, HELD IN MAY 2019 WAS PATHS TO TREATMENT FOR TRAUMATIC BRAIN INJURY(S) WITH A FOCUS ON THE TAXONOMY AND NOSOLOGY OF THE CHRONIC SEQUELAE, CHALLENGES AND OPPORTUNITIES IN CLINICAL PRACTICE AND DEVELOPMENT, AND ETIOLOGY AND MECHANISM OF PERSISTENT SYMPTOMS. AS MEASUREMENT TOOLS ADVANCE, RESEARCH HAS BEEN ABLE TO FOCUS ON DIFFERENT TYPES OF INJURY, BEYOND THE MILD, MODERATE, AND SEVERE CLASSIFICATIONS OF TBI. TO AUGMENT AND SUPPORT THE MANY EFFORTS ACROSS FIELDS AND ORGANIZATIONS OVER THE PAST DECADE, WE AIM TO MAP A CONSENSUS BLUEPRINT TO DRIVE TRANSLATIONAL SCIENCE FOR TBI.ADAPTIVE PLATFORM TRIALS:CVB IS SPEARHEADING THE DESIGN AND APPLICATION OF "SMART- OR "ADAPTIVE-" CLINICAL TRIALS FOR NEUROPSYCHIATRIC AND NEURODEGENERATIVE CONDITIONS. THESE STUDIES INCLUDE A PROSPECTIVELY PLANNED OPPORTUNITY FOR MODIFICATION OF ONE OR MORE SPECIFIED ASPECTS OF THE STUDY DESIGN BASED ON DATA (USUALLY INTERIM DATA) COLLECTED FROM SUBJECTS IN THE STUDY. TO EXECUTE SUCH A PROGRAM, OUR CENTRALLY-MANAGED PLATFORM CLINICAL TRIAL INFRASTRUCTURE (BRAIN-NET) WILL BE LEVERAGED TO CONDUCT STUDIES ACROSS BRAIN CONDITIONS AND POPULATIONS INCLUDING ACADEMIC, PRIVATE, VA, AND POTENTIALLY MILITARY RESEARCH CENTERS.CURRENTLY, ONLY TWO DRUGS ARE APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OF PTSD, ALTHOUGH BOTH ARE ONLY MODESTLY EFFECTIVE IN TREATING MILITARY-RELATED PTSD. OVER THE PAST 17 YEARS, INDIVIDUAL ACADEMIC INVESTIGATORS AND COMPANIES HAVE NOT DELIVERED ALTERNATIVE FDA-APPROVED DRUGS. IN RESPONSE TO THIS UNMET NEED, OUR PROGRAM WILL TEST MULTIPLE DRUGS TO ADVANCE THEM THROUGH REGULATORY APPROVAL. IN THE FUTURE, WE WILL EXPAND OUR EFFORTS TO OTHER THERAPEUTIC SOLUTIONS (E.G. DEVICES, ALTERNATIVE THERAPIES), THROUGH OUR EVIDENCE-DRIVEN CLINICAL TRIAL NETWORK INFRASTRUCTURE.IN SEPTEMBER 2018, THE U.S. ARMY MEDICAL MATERIEL DEVELOPMENT ACTIVITY, A SUBORDINATE COMMAND OF THEU.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND, ANNOUNCED AN AWARD OF DEFENSE HEALTH AGENCY UNDER AN OTHER TRANSACTION AGREEMENT, TO CVB TO CONDUCT PHASE 2 TESTING OF DRUGS FOR THE TREATMENT OF MILITARY-RELATED POST-TRAUMATIC STRESS DISORDER USING AN INNOVATIVE TRIAL DESIGN. BEST BIOMARKER PTSD STUDY:DESPITE THE EFFICACY OF PSYCHOTHERAPY AS FIRST-LINE TREATMENT FOR PTSD, LARGE INTER-INDIVIDUAL DIFFERENCES IN OUTCOMES EXIST, WITH ROUGHLY 50% OF PATIENTS RESPONDING TO TREATMENT AND FEWER THAN THAT FULLY REMITTING. THIS GRANT SUPPORTED THE DEVELOPMENT OF A RESPONSE DIAGNOSTIC TEST BASED ON PRELIMINARY FINDINGS FOR A COMBINATION COGNITIVE/IMAGING MARKER RESULTING FROM CVB'S INVESTMENT IN THE COHEN VETERANS CENTER STUDY AT NYU/STANFORD. THE PROGRAM, CONCLUDING IN LATE 2019, INCLUDES A CLINICAL STUDY AT TWO CENTERS OF OVER 200 SUBJECTS TO REPLICATE THE INITIAL FINDING, AND IS SEEKING QUALIFICATION VIA THE FOOD AND DRUG ADMINISTRATION ("FDA") GUIDANCE TO SUPPORT THE COMMERCIALIZATION AND/OR AVAILABILITY OF THE TEST FOR CLINICAL PRACTICE AND RESEARCH AND DEVELOPMENT. PTSD GENETICS PROGRAM:THE PSYCHIATRIC GENETICS CONSORTIUM-PTSD WORKING GROUP - BROAD INSTITUTE COLLABORATION IS SUPPORTING THE LARGEST GLOBAL GENOME WIDE ASSOCIATION STUDY ("GWAS") OF PTSD TO DATE WITH DATA FROM OVER 200,000 INDIVIDUALS ANALYZED. THE MAIN GOAL IS TO UNCOVER THE GENETIC UNDERPINNINGS OF PTSD RISK AND PUBLISH ALL RESULTS. SUBSEQUENT TO YEAR END, SEMINAL FINDINGS OF THE FIRST PTSD GENETIC RISK LOCI FROM THIS PROGRAM WERE PUBLISHED IN NATURE COMMUNICATIONS IN OCTOBER 2019.THE PROGRAM WITH THE BROAD INSTITUTE WAS EXTENDED IN FY 2018 TO INCLUDE FUNCTIONAL GENOMICS STUDIES OF IDENTIFIED GENETIC MARKERS AS WELL AS GENETIC EXPRESSION ANALYSIS OF AMYGDALA CELLULAR CIRCUITS IN ORDER TO INITIATE THE IDENTIFICATION OF POTENTIAL TARGETS FOR THERAPEUTIC INTERVENTION IN PTSD.RTMS BIOMARKER PTSD STUDY:THIS PROJECT SEEKS TO DEVELOP TREATMENT PREDICTION INDICES AND EXPLORE TREATMENT TRACKING AND MEDIATING INDICES USING A COMBINATION OF A VERBAL MEMORY TEST AND RESTING AND TMS-EVOKED EEG DATA RECORDED BEFORE AND AFTER RTMS TREATMENT FOR PTSD. SPECIFICALLY, THIS IS AN ADD-ON STUDY, AT SELECTED SITES, INTEGRATED INTO A PIVOTAL STUDY SEEKING FDA APPROVAL OF H7 DEEP TMS COIL AS A TREATMENT FOR PTSD.NATIONAL NEUROIMAGING NORMATIVE LIBRARY PROGRAM:CVB HAS CREATED AN IMAGING REFERENCE LIBRARY ESSENTIAL TO THE DEVELOPMENT OF EFFECTIVE CLINICAL IMAGING TOOLS FOR DIAGNOSING AND MANAGING PATIENTS WITH BRAIN DISORDERS. ADVANCED NEUROIMAGING CAN NOW DETECT MICROSCOPIC CHANGES IN BRAIN STRUCTURE CAUSED BY TRAUMA OR DISEASE. THESE ADVANCED IMAGING APPROACHES INCLUDE DIFFUSION TENSOR IMAGING (DTI), FUNCTIONAL CONNECTIVITY, PERFUSION WEIGHTED IMAGING, AND VOLUMETRIC IMAGING. DESPITE THEIR PROMISE, THESE ADVANCED APPROACHES ARE CURRENTLY PRIMARILY CONFINED TO RESEARCH USE. THE NUMERICAL NATURE OF THE INFORMATION THESE ADVANCED IMAGING APPROACHES YIELD IS DIFFICULT TO TRANSLATE FROM THE STUDY OF GROUPS OF INDIVIDUALS TO A SINGLE PATIENT WITHOUT A REFERENCE. THE IMAGING DATABASE IS BASED ON THE RESULTS OF A NATIONAL STUDY OF NORMATIVE INDIVIDUALS, SPONSORED BY CVB AT UNIVERSITY OF VIRGINIA, BAYLOR UNIVERSITY AND UNIVERSITY OF UTAH. STANDARDIZED ADVANCED NEUROIMAGING SCANS ON 3,000 ADULT VOLUNTEERS WHO HAVE NOT BEEN AFFECTED BY BRAIN TRAUMA OR DISEASE WERE PERFORMED. THE RESULTING IMAGING DATA, ALONG WITH DEMOGRAPHIC INFORMATION AND THE RESULTS OF NEUROCOGNITIVE ASSESSMENTS, IS FORMING A LIBRARY DOCUMENTING POPULATION VARIATION IN BRAIN STRUCTURE AND FUNCTION AS MEASURED BY THESE ADVANCED IMAGING METHODS.THROUGH THIS IMAGING DATABASE, IT IS OUR GOAL TO ADVANCE NEUROIMAGING TO DRAMATICALLY IMPROVE THE IDENTIFICATION OF AFFECTED INDIVIDUALS AND ALLOW PHYSICIANS TO OBJECTIVELY AND EFFICIENTLY DIAGNOSE CONDITIONS SUCH AS TBI, DEMENTIA AND OTHER BRAIN DISORDERS WHERE BRAIN STRUCTURE IS DETECTED VIA MRI.PTSD TIA-1 PROGRAM:CVB HAS FUNDED COLUMBIA UNIVERSITY TO SUPPORT A MULTI-PRONGED SCIENTIFIC PROGRAM THAT WILL STUDY THE INTERPLAY BETWEEN THE TIA GENE AND PROTEIN PRODUCTS, STRESS GRANULES, STRESS CIRCUITS AND PTSD AND TBI. FURTHER RESEARCH WILL LOOK AT WAYS TO MAINTAIN THE GENE'S PROTECTIVE FEATURES, WHICH COULD ULTIMATELY LEAD TO THE DEVELOPMENT OF DRUGS TO PREVENT AND TREAT PTSD.PTSD AND TBI PRECLINICAL MODELING PROGRAM:ANIMAL MODELS OF PSYCHIATRIC DISORDERS OFFER A COMPLEMENTARY RESEARCH MODALITY THAT SUPPORTS CLINICAL RESEARCH. IN ORDER TO ACHIEVE A SATISFACTORY DEGREE OF VALIDITY AND RELIABILITY, ANIMAL MODELS OF COMPLEX AND INTRICATE PSYCHIATRIC DISORDERS, SUCH AS PTSD, MUST FULFILL CERTAIN CRITERIA: PATHOGENIC PROCESSES MUST BE OBSERVABLE AND MEASURABLE, AND MUST RELIABLY REFLECT CLINICAL SYMPTOMATOLOGY, AND PHARMACOLOGICAL AGENTS THAT ARE KNOWN TO AFFECT SYMPTOMS IN HUMAN SUBJECTS, SHOULD MODULATE THESE PROCESSES. CVB HAS ESTABLISHED THE ALLIANCE FOR MODELS OF PTSD, INNOVATIVE TECHNOLOGIES AND UNIFORM PRACTICES ("AMP-IT- UP") TO SUPPORT PRECLINICAL MODEL DEVELOPMENT. MULTIPLE SUB-GRANT AWARDS HAVE BEEN ISSUED TO SUPPORT THE MISSION OF THIS PROGRAM.IN FY 2021, WE PLAN TO EXPAND THE PROGRAM TO EVALUATION OF ANIMAL MODELS OF TBI, PARTICULARLY BLAST MODELS ASSOCIATED WITH MILITARY TRAUMA. COMPUTATIONAL MODELING & DATA SCIENCES:CVB HAS ESTABLISHED AN INTRAMURAL DATA SCIENCES PROGRAM TO BUILD MACHINE-LEARNING AND ARTIFICIAL INTELLIGENCE BASED PREDICTIVE MODELS OF DISEASE. THIS PROGRAM BUILDS ON OUR ORIGINAL ORION MS BIO-MODELLING PROGRAM AND FOCUSES ON MODELS OF PTSD, TBI, PARKINSONS AND DEMENTIA AND OTHER CONDITIONS.MULTIPLE SCLEROSIS (MS) 1.0:THE ORION BIONETWORKS FLAGSHIP PROGRAM SUCCESSFULLY PILOTED THE ESTABLISHMENT OF A MULTIPLE SCLEROSIS ("MS") BIONETWORK COMPRISED OF ACADEMIC (NEUROSCIENCE INSTITUTE OF THE BRIGHAM AND WOMEN'S HOSPITAL), ADVOCACY (ACCELERATED CURE PROJECT FOR MS), COMPUTATIONAL (GNS HEALTHCARE, METACELL, THOMSON REUTERS), INFORMATICS (CONVERGE BY DELOITTE, RANCHO BIOSCIENCES, EXAPTIVE), AND ONLINE PATIENT COMMUNITY PARTNERS (PATIENTSLIKEME [PLM]). DE-IDENTIFIED HIPPA-COMPLIANT DATA FROM THREE DATABASES WERE CURATED AND LOADED INTO A CLOUD-BASED DATA KNOWLEDGE MANAGEMENT SYSTEM. THE INTEGRATED REPOSITORY INCLUDES 9,000 SUBJECTS WITH MS AND RELATED CONDITIONS. THE ALLIANCE DEVELOPED A ROADMAP FOR JOINT EXECUTION WITH SPECIFIC SCIENTIFIC AIMS. TO DATE, THE ALLIANCE HAS GENERATED THREE MODELS BASED ON THE DATA REPOSITORY USING DIFFERENT ALGORITHMIC APPROACHES: PHENOTYPIC PROGNOSTIC MODEL AND TWO MOLECULAR PROGNOSTIC MODELS.PARKINSON'S PROGRESSION MARKERS INITIATIVE (PPMI) DATA SCIENCE MODELING GROUP:EXISTING DIAGNOSES FOR COMPLEX BRAIN DISORDERS SUCH AS PARKINSON'S DISEASE (PD) FOCUS ON UNDERSTANDING CLUSTERS OF MAJOR SYMPTOMS. IN ORDER TO DRIVE PROGRESS IN THE DEVELOPMENT OF NEW TREATMENTS IT IS IMPORTANT TO UNDERSTAND THE ROLE OF SPECIFIC BIOLOGICAL PROCESSES IN DETERMINING PATIENT OUTCOMES. IN THIS PROGRAM WE MODEL THE MICHAEL J. FOX FOUNDATION (MJFF) SPONSORED PARKINSON'S PROGRESSION MODEL INITIATIVE (PPMI) STUDY. THE STUDY HAS EVALUATED PARTICIPANTS' CLINICAL STATUS WHILE COLLECTING IMAGING, BEHAVIORAL, 'OMICS AND OTHER ASSESSMENTS LONGITUDINALLY SINCE 2010. IN OUR ALIGNED MISSIONS TO ADVANCE BRAIN HEALTH, MJFF SELECTED COHEN VETERAN'S BIOSCIENCE DATA SCIENCE TEAM TO LEVERAGE THIS COHORT TOGETHER WITH A MULTI-DISCIPLINARY APPROACH TO QUANTITATIVELY EXPLORE, EVALUATE, AND PREDICT DISEASE TRAJECTORY, RISK FACTORS, AND SUBTYPES. GIVEN THE BREADTH AND DEPTH OF THE PPMI DATA AND RICH OPPORTUNITIES TO DEVELOP IMPACTFUL DISEASE MODELS, THE TEAM USE THEIR SUBJECT MATTER EXPERTISE ACROSS TRANSLATIONAL SCIENCE TO GENERATE INSIGHTS FROM 'OMICS, IMAGING, GENETIC AND CLINICAL DATA BY INTEGRATING TECHNIQUES ACROSS ADVANCED STATISTICS, MACHINE LEARNING, AND COMPUTATIONAL MODELING TO FACILITATE PD BIOMARKER DISCOVERY AND DEEPEN OUR UNDERSTANDING OF DISEASE PROGRESSION.PTSD AND TBI KNOWLEDGEMAP:THE BRAINTRAUMA KNOWLEDGEMAP PROJECT WITH FRAUNHOFER SCAI AND EXAPTIVE IS USING INFORMATION TECHNOLOGY AND VISUALIZATION TO BUILD AN INNOVATIVE NEW INTERACTIVE TOOL TO EXTRACT INFORMATION FROM PUBLISHED PAPERS FOR THE RESEARCH COMMUNITY. THE WORK WAS EXTENDED TO INCLUDE EXTRACTION OF PTSD BIOMARKER AND TBI LITERATURE IN FY 2018.GLOBAL PRECLINICAL DATA FORUM:THE GLOBAL PRECLINICAL DATA FORUM IS A JOINTLY SPONSORED U.S. AND EUROPEAN INITIATIVE THAT ENCOURAGES GLOBAL COLLABORATION TO ADDRESS THE CHALLENGE OF ENSURING THAT PRECLINICAL RESEARCH IS REPRODUCIBLE, ROBUST AND TRANSLATABLE TO SUPPORT DISEASE RESEARCH UTILITY FOR CLINICAL RESEARCH AND DEVELOPMENT (R&D). IT SUPPORTS BEST RESEARCH PRACTICES, THE DEVELOPMENT AND IMPLEMENTATION OF DATA QUALITY STANDARDS, PRECLINICAL DATA AND TECHNOLOGICAL PLATFORMS, AND TRAINING PROGRAMS FOR THE NEUROSCIENCE COMMUNITY WITH THE GOAL OF ENHANCING THE DATA UTILITY DERIVED FROM PRECLINICAL MODELS. IN 2018, WE SUPPORTED THE WORLD'S FIRST NEGATIVE DATA PRIZE AS AN INCENTIVE FOR PRECLINICAL RESEARCHERS TO PUBLISH "NEGATIVE DATA" RESULTS TO ENSURE ALL NEUROSCIENCE STUDIES PROPERLY ADVANCE KNOWLEDGE.THIS FIRST NEGATIVE DATA PRIZE WAS AWARDED TO LAURA LUYTEN AND TOM BECKERS (KU LEUVEN, BELGIUM) FOR THE FOLLOWING PAPER:LUYTEN L, BECKERS T (2017) A PREREGISTERED, DIRECT REPLICATION ATTEMPT OF THE RETRIEVAL-EXTINCTION EFFECT IN CUED FEAR CONDITIONING IN RATS. NEUROBIOLOGY OF LEARNING AND MEMORY 144: 208-215. 18881114 1 1 0 1 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 1 26 0 25 1 0 0 0 0 0 0 0 0 0 0 0 0 X 4 2 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA NY X X GELMAN ROSENBERG AND FREEDMAN CPA 3019519090 4550 MONTGOMERY AVENUE SUITE 650N BETHESDA MD 20814 MAGALI HAAS MD PHD CEO & PRESIDENT 60.00 X X 617505 0 16361 THERESA FRANGIOSA SECRETARY 9.00 X X 0 0 0 MICHAEL SULLIVAN TREASURER 1.00 X X 0 0 0 DOUGLAS HAYNES BOARD MEMBER 1.00 X 0 0 0 ANDREAS JEROMIN PHD CHIEF SCIENTIFIC OFFICER 40.00 X 437015 0 16553 ALLYSON GAGE PHD CHIEF MEDICAL OFFICER 40.00 X 505708 0 25253 DANIELA BRUNNER PHD EXECUTIVE DIRECTOR OF DIGITAL HEALTH 40.00 X 164773 0 9886 SEAN MCCREERY FORMER CHIEF OPERATIONS OFFICER 40.00 X 127928 0 21827 HEATHER LASSETER PHD ASSOC. DIRECTOR, SCIENTIFIC PROGRAMS 40.00 X 124437 0 15075 PATRICIA KABITZKE SR. SCIENTIFIC PROGRAM MANAGER 40.00 X 118439 0 32075 KEITH ROBINSON DIRECTOR OF OPERATIONS 40.00 X 116473 0 6700 2212278 0 143730 8 0 1 0 ICONIC EVENT STUDIOS 1861 SUNSET PLAZA DRIVE LOS ANGELES CA 90069 EVENT MANAGEMENT 956925 MORGAN LEWIS AND BOCKIUS LLP 1701 MARKET STREET PHILADELPHIA PA 19103 LEGAL SERVICES 855766 DEEP NET AI LTD 18 MICKLEHOME ALREWAS BURTON ON TR STAFFDORDSHIRE UNITED KINGDOM UK DE13 7AT DATA SCIENCE CONSULTANT 281204 GRF CPA'S & ADVISORS 4550 MONTGOMERY AVENUE SUITE 800 NORTH BETHESDA MD 20814 ACCOUNTING AND BOOKKEEPING 214742 CLARIVATE ANALYTICS (US) LLC 1500 SPRING GARDEN STREET 4TH FLOOR PHILADELPHIA PA 19130 ANALYTIC SERVICES 169735 8 700789 20094263 20795052 98872 98872 GRANT REFUNDS 900099 145524 145524 145524 21039448 145524 0 98872 X 2724238 2724238 62603 62603 1657119 1495480 129311 32328 2733498 2439868 283546 10084 146644 132030 13688 926 165946 146186 17937 1823 290861 260580 27488 2793 769440 732749 36691 320706 6542 314164 87500 87500 8072902 7963926 106685 2291 239432 58691 180200 541 57192 55369 1697 126 461464 430178 31286 509351 441527 65561 2263 1655847 1654673 1174 9514 9120 358 36 34879 15053 19664 162 RESEARCH SUPPLIES 164801 164801 BAD DEBT EXPENSE 7000 7000 20170937 18881114 1236450 53373 607164 465961 7142648 16036550 8208158 7527477 258542 61526 59740 9514 0 50226 136852 48529 16353364 24190269 1415169 2672945 4605358 10118262 0 197714 6020527 12988921 X 382880 840992 9949957 10360356 10332837 11201348 16353364 24190269 868511 0 X X 0 1 X 1 0 X 68535 31399759 4366629 16828176 20795052 73458151 68535 31399759 4366629 16828176 20795052 73458151 68352810 5105341 17365 98872 116237 73574388 1500 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 87500 87500 20083437 20170937 1000000 250000 0 0 893383 1000000 1893383 2840075 90000 87500 177500 223346 250000 473346 710019 39973 4755 35218 19767 4759 15008 50226 X 21039448 0 21039448 0 21039448 20170937 0 20170937 0 20170937 PART X, LINE 2: TAX POSITION: THE ORGANIZATION CURRENTLY EVALUATES ALL TAX POSITIONS, AND MAKES A DETERMINATION REGARDING THE LIKELIHOOD OF THOSE POSITIONS BEING UPHELD UNDER REVIEW. THE PRIMARY TAX POSITION MADE BY THE ORGANIZATION IS THE EXISTENCE OF UNRELATED BUSINESS INCOME TAX AND THE ORGANIZATION'S STATUS AS A TAX-EXEMPT ORGANIZATION UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. FOR THE YEAR PRESENTED, THE ORGANIZATION HAS NOT RECOGNIZED ANY TAX BENEFITS OR LOSS CONTINGENCIES FOR UNCERTAIN TAX POSITIONS BASED ON THIS EVALUATION. 1 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION N/A 60114 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION N/A 2489 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 1 PROGRAM ACTIVITIES PAYMENT FOR CONTRACTED SERVICES 250080 0 1 0 0 0 1 312683 0 312683 EUROPE (BELGIUM) HIGH-DENSITY RECORDING IN THE SPS MODEL OF PTSD 60114 WIRE TRANSFER N/A N/A NORTH AMERICA (CANADA) DEMENTIA RESEARCH AWARD 2489 WIRE TRANSFER N/A N/A 0 2 0 0 0 0 0 0 PART I, LINE 2: THE ORGANIZATION REQUIRES GRANTEES TO REGULARLY PROVIDE QUALITATIVE AND QUANTITATIVE REPORTS DESCRIBING HOW FUNDS ARE BEING SPENT AND THE RESULTS THE GRANTEE HAS ACHIEVED. PROGRESS IS MEASURED AGAINST ORIGINAL AND REVISED GRANT PROPOSALS. CONTINUATION OF FUNDING IS DEPENDENT ON RESULTS AND ACCURATE, TIMELY REPORTING. 1 UNIVERSITY OF CINCINNATI PO BOX 932641 CLEVELAND OH 44193 316000989 GOVERNMENT 32669 N/A N/A THE ROLE OF STRESS HORMONES AND DOPAMINE IN A NOVEL GENETIC RAT MODEL OF PTSD REGENTS OF THE UNIVERSITY OF MICHIGAN 1000 VICTORS WAY SUITE 1A ANN ARBOR MI 48108 386006309 501(C)3 76330 N/A N/A HIGH-DENSITY RECORDING IN THE SPS MODEL OF PTSD CHILDREN'S HOSPITAL OF PHILADELPHIA PO BOX 8500 PHILADEPHIA PA 19178 231352166 501(C)3 300757 N/A N/A VALIDATING CONSTRUCTS RELEVANT TO PTSD IN A MODEL OF INDIVIDUAL DIFFERENCES IN RESPONSE TO SOCIAL DEFEAT IN RATS NATIONAL ASSOCIATION OF VETERANS' RESEARCH AND EDUCATION FOUNDATION 1717 K ST NW SUITE 900 WASHINGTON DC 20006 521784596 C CORP 30000 N/A N/A NAVRED ANNUAL CONFERENCE SPONSORSHIP EARLY SIGNAL FOUNDATION INC 315 W 36TH ST NEW YORK NY 10018 813198566 501(C)3 128000 N/A N/A BIOSENSORS AND MOBILE HEALTH PLATFORM FOR BRAIN DISEASES AMERICAN COLLEGE OF RADIOLOGY (ACR) 1818 MARKET ST STE 1720 PHILADELPHIA PA 19103 362261602 501(C)3 262528 N/A N/A CONDUCT STUDY TO ESTABLISH A NATIONAL NORMATIVE NEUROIMAGING LIBRARY UNIVERSITY OF CHICAGO 6054 SOUTH DREXEL AVE CHICAGO IL 60637 362177139 501(C)3 883650 N/A N/A PROVIDE SERVICES AND SUPPORT FOR BRAIN COMMONS (DATA-REPOSITORY) THE BROAD INSTITUTE OF MIT AND HARVARD 415 MAIN STREET CAMBRIDGE MA 02142 263428781 501(C)3 528915 N/A N/A PTSD RESEARCH PROGRAMS LOUISIANA STATE UNIVERSITY 433 BOLIVAR STREET NEW ORLEANS LA 70112 726087770 GOVERNMENT 125884 N/A N/A PTSD-AUD COMORBIDITY MODEL DEVELOPMENT HARVARD UNIVERSITY 1033 MASSACHUSETTS AVE 2ND FLOOR CAMBRIDGE MA 02138 042103580 501(C)3 148805 N/A N/A ADVANCING THE STUDY OF DEPLOYMENT TRAUMA IN THE TRACTS COHORT UNIVERSITY OF CALIFORNIA SANTA BARBARA PHELPS HALL 1110 SANTA BARBARA CA 93106 956006145 GOVERNMENT 53000 N/A N/A STUDY OF TAU BIOLOGY AND PATHOLOGY FOR AD, TBI AND OTHER DISORDERS COLUMBIA UNIVERSITY 615 WEST 131ST STREET 3RD FLOOR NEW YORK NY 10027 135598093 501(C)3 46000 N/A N/A PTSD RESEARCH PROGRAMS UNIVERSITY OF VIRGINIA PO BOX 400202 CHARLOTTESVILLE VA 22904 546001796 501(C)3 28598 N/A N/A NORMATIVE NEUROIMAGING LIBRARY BOSTON VA RESEARCH INSTITUTE 5 POST OFFICE SQUARE SUITE 1628 BOSTON MA 02109 043081524 501(C)3 79103 N/A N/A ADVANCING THE STUDY OF DEPLOYMENT TRAUMA IN THE TRACTS COHORT 13 1 PART I, LINE 2: THE ORGANIZATION REQUIRES GRANTEES TO REGULARLY PROVIDE QUALITATIVE AND QUANTITATIVE REPORTS DESCRIBING HOW FUNDS ARE BEING SPENT AND THE RESULTS THE GRANTEE HAS ACHIEVED. PROGRESS IS MEASURED AGAINST ORIGINAL AND REVISED GRANT PROPOSALS. CONTINUATION OF FUNDING IS DEPENDENT ON RESULTS AND ACCURATE, TIMELY REPORTING. X X X 0 0 0 0 0 0 0 0 0 MAGALI HAAS MD PHD CEO & PRESIDENT 441005 0 176500 0 0 0 16361 0 0 0 633866 0 0 0 ANDREAS JEROMIN PHD CHIEF SCIENTIFIC OFFICER 309015 0 128000 0 0 0 0 0 16553 0 453568 0 0 0 ALLYSON GAGE PHD CHIEF MEDICAL OFFICER 348208 0 157500 0 0 0 16500 0 8753 0 530961 0 0 0 DANIELA BRUNNER PHD EXECUTIVE DIRECTOR OF DIGITAL HEALTH 111883 0 52890 0 0 0 9886 0 0 0 174659 0 0 0 PATRICIA KABITZKE SR. SCIENTIFIC PROGRAM MANAGER 118439 0 0 0 0 0 7404 0 24671 0 150514 0 0 0 FRANGIOSA & ASSOCIATES OWNER IS AN OFFICER OF THE ORGANIZATION 101475 PROVIDED DISCOUNTED STRATEGIC CONSULTING SERVICES TO ORGANIZATION. 0 FORM 990, PART VI, SECTION B, LINE 11B THE BOARD OF DIRECTORS REVIEWED AND APPROVED THE FORM 990 PRIOR TO ITS FILING. THE FORM 990 WAS THEN AUTHORIZED AND SIGNED BY THE ORGANIZATION'S CEO & PRESIDENT. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD OF DIRECTORS REQUIRES AN ANNUAL DECLARATION FROM ALL BOARD MEMBERS AND SENIOR MANAGEMENT AS TO THE EXISTENCE AND DISCLOSURE OF ANY POTENTIAL CONFLICTS OF INTEREST. THE BOARD MEMBERS SIGN A DISCLOSURE STATEMENT. ANY POTENTIAL CONFLICTS ARE DISCUSSED BY THE DIS-INTERESTED BOARD MEMBERS, WHILE THE PARTY IN POTENTIAL CONFLICT IS REQUIRED TO LEAVE THE ROOM. BOARD MEETING MINUTES WILL DOCUMENT THE DISCUSSION AND DECISION MAKING PROCESS. IN THE EVENT OF A POTENTIAL CONFLICT, PROCEDURES TO OBTAIN COMPETITIVE BIDS AND DILIGENCE ON FAIR MARKET VALUE WILL BE ESTABLISHED. FORM 990, PART VI, SECTION B, LINE 15 CVB'S EXECUTIVE COMPENSATION PROGRAM IS ADMINISTERED BY THE BOARD OF DIRECTORS. THE BOARD IS RESPONSIBLE FOR ESTABLISHING AND MAINTAINING A COMPETITIVE COMPENSATION PROGRAM FOR THE KEY EXECUTIVES OF THE ORGANIZATION. THE BOARD MEETS AS NEEDED TO REVIEW THE COMPENSATION PROGRAM AND MAKE RECOMMENDATIONS FOR ANY CHANGES, AS APPROPRIATE. A PERFORMANCE EVALUATION IS CONDUCTED AND REVIEWED EACH YEAR AND IS INTENDED TO ENSURE THAT THE COMPENSATION PROGRAM FALLS WITHIN A REASONABLE RANGE OF COMPETITIVE PRACTICES FOR COMPARABLE POSITIONS AMONG SIMILARLY SITUATED ORGANIZATIONS. FOLLOWING THIS REVIEW, THE BOARD REVIEWS AND APPROVES, FOR SELECTED KEY EXECUTIVES, BASE SALARIES AND ANNUAL INCENTIVE OPPORTUNITY ADJUSTMENTS, AND OBJECTIVES AND GOALS UPCOMING YEAR'S ANNUAL INCENTIVE PLAN. THE BOARD REVIEWS AND RECOMMENDS TO THE BOARD SALARY APPROVAL AND INCENTIVE AWARDS FOR THE CEO/PRESIDENT AND SELECTED KEY SENIOR STAFF. FORM 990, PART VI, SECTION C, LINE 19 UPON REQUEST AND FORMS AVAILABLE THROUGH CHARITY NAVIGATOR WEBSITE AS WELL. FORM 990, PART IX, LINE 11G PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 3,451. MANAGEMENT AND GENERAL EXPENSES 84,137. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 87,588. RESEARCH COLLABORATION EXPENSES: PROGRAM SERVICE EXPENSES 6,016,814. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 6,016,814. CONTRACTED SERVICES: PROGRAM SERVICE EXPENSES 1,943,661. MANAGEMENT AND GENERAL EXPENSES 22,548. FUNDRAISING EXPENSES 2,291. TOTAL EXPENSES 1,968,500. EARLY SIGNAL LLC 1 BROADWAY 14TH FLOOR CAMBRIDGE MA 02142 TO HOLD INTELLECTUAL PROPERTY MA 0 0 COHEN VETERANS BIOSCIENCE INC